Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM2F8XZ)

• Drug Name: Salicyclic acid Drug Info
• Synonyms: Salicylic acid; salicylic acid; 2-Hydroxybenzoic acid; 69-72-7; o-hydroxybenzoic acid; 2-Carboxyphenol; o-Carboxyphenol; Salonil; Rutranex; Retarder W; Keralyt; Freezone; Duoplant; Saligel; Ionil; Psoriacid-S-stift; salicylate; Stri-Dex; Salicylic acid soap; Benzoic acid, 2-hydroxy-; Salicylic acid collodion; Verrugon; Phenol-2-carboxylic acid; Acidum salicylicum; Trans-Ver-Sal; Orthohydroxybenzoic acid; 2-Hydroxybenzenecarboxylic acid; Acido salicilico; Ionil-Plus; Salicylic acid, tech; Kyselina salicylova; Clear away wart remover; Duofil wart; Domerine; Duofilm; Occlusal; SAX; Salicylate; Sebucare; Sebulex; Acido salicilico [Italian]; Advanced pain relief callus removers; Advanced pain relief corn removers; Akurza Cream; Akurza Lotion; DHS Sal Shampoo; DuoPlant Gel; Duofil wart remover; Hydrisalic Gel; Ionil plus; Kyselina salicylova [Czech]; Mediplast pads; O Hydroxybenzoic Acid; Ortho Hydroxybenzoic Acid; Retarder SAX; Salex Cream; Salex Lotion; CMC_13852; K 537; ATA fraction 10, ammonium salt; Acid, Salicylic; Acido o-idrossibenzoico; Acido o-idrossibenzoico [Italian]; Kyselina 2-hydroxybenzoova; Kyselina 2-hydroxybenzoova [Czech]; O-Carboxyphenol; O-hydroxybenzoic acid; Ortho-Hydroxybenzoic Acid; P&S Shampoo; Phenol derivative, 7; Propa pH Peel-Off Acne Mask; SALICYLIC ACID (SEE ALSO ALPHA HYDROXY ACIDS); SALICYLIC ACID, ACS; Salicylic acid & Sulfur Soap; Salicylic acid (TN); Salicylic acid [USAN:JAN]; Acid, 2-Hydroxybenzoic; Acid, o-Hydroxybenzoic; Acid, ortho-Hydroxybenzoic; BENZOIC ACID,2-HYDROXY SALICYLIC ACID; Dr Scholl's callus removers; Dr Scholl's corn removers; Dr Scholl's wart remover kit; Salicylic acid (6CI,8CI); Salicylic acid (JP15/USP); Alpha/Beta Hydroxy Acids (Glycolic Acid, Salicylic Acid); Salicylic acid-ring-UL-14C; ALPHA/BETA HYDROXY ACIDS (SALICYLIC ACID) (SEE ALPHA/BETA HYDROXY ACIDS); Benzoic acid, 2-hydroxy-(9CI); E9A559BE-383B-4F83-BC02-3031D03D558A; 2 Hydroxybenzoic Acid; 2-hydroxy(1-14c)benzoic acid; SALICYLATE

Indication

Disease Entry	ICD 11	Status	REF
Acne vulgaris	ED80	Approved	[1]
Acute coronary syndrome	BA41	Approved	[2]
Adenomatous colon polyp		Approved	[2]
Allergic rhinitis	CA08.0	Approved	[2]
Back pain	ME84.Z	Approved	[2]
Common cold	CA00	Approved	[2]
Fever	MG26	Approved	[2]
Headache	8A80-8A84	Approved	[2]
Keratinization disease		Approved	[2]
Migraine disorder		Approved	[2]
Myocardial infarction	BA41-BA43	Approved	[3]
Osteoarthritis	FA00-FA05	Approved	[2]
Pain	MG30-MG3Z	Approved	[2]
Pityriasis simplex		Approved	[2]
Seborrhoeic dermatitis	EA81	Approved	[4]
Tinea corporis	1F28.Y	Approved	[2]
Colon cancer	2B90.Z	Investigative	[5]
Rheumatoid arthritis	FA20	Investigative	[6]
Synovitis		Investigative	[2]
Tinea pedis	1F28.2	Investigative	[2]

• Therapeutic Class: Antiinflammatory Agents
• Cross-matching ID:
  PubChem CID: 338
  ChEBI ID: CHEMBL424
  CAS Number: CAS 69-72-7
  TTD Drug ID: DM2F8XZ
  VARIDT Drug ID: DR00556
  INTEDE Drug ID: DR1458

Molecule-Related Drug Atlas

Drug(s) Targeting Carbonic anhydrase VI (CA-VI)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sulfamylon	DMIO1K0	Bacterial infection	1A00-1C4Z	Approved	[21]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[22]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[23]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[24]
SAR566658	DM6Q295	Solid tumour/cancer	2A00-2F9Z	Phase 2	[25]
FERULIC ACID	DMJC7NF	Discovery agent	N.A.	Patented	[23]
SPERMINE	DMD4BFY	N. A.	N. A.	Terminated	[26]
ELLAGIC ACID	DMX8BS5	Discovery agent	N.A.	Investigative	[23]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[27]
CATECHIN	DMY38SB	Discovery agent	N.A.	Investigative	[22]

Drug(s) Targeting Carbonic anhydrase I (CA-I)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ethoxzolamide	DMVO4ED	Glaucoma/ocular hypertension	9C61	Approved	[28]
Dichlorphenamide	DMH7IDQ	Chronic glaucoma	9C61.0Z	Approved	[28]
Methazolamide	DM7J2TA	Glaucoma/ocular hypertension	9C61	Approved	[29]
Acetazolamide	DM1AF5U	Absence epilepsy		Approved	[28]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[22]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[23]
CG-100649	DMIKMA9	Arthritis	FA20	Phase 3	[30]
PHENOL	DM1QSM3	N. A.	N. A.	Phase 2/3	[22]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[24]
SULFAMIDE	DMMAS3K	N. A.	N. A.	Phase 1	[31]

Drug(s) Targeting Carbonic anhydrase XII (CA-XII)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sulfamylon	DMIO1K0	Bacterial infection	1A00-1C4Z	Approved	[32]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[22]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[23]
PHENOL	DM1QSM3	N. A.	N. A.	Phase 2/3	[22]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[24]
FERULIC ACID	DMJC7NF	Discovery agent	N.A.	Patented	[23]
ELLAGIC ACID	DMX8BS5	Discovery agent	N.A.	Investigative	[23]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[27]
CATECHIN	DMY38SB	Discovery agent	N.A.	Investigative	[22]
GALLICACID	DM6Y3A0	Discovery agent	N.A.	Investigative	[23]

Drug(s) Targeting Carbonic anhydrase II (CA-II)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sulfamylon	DMIO1K0	Bacterial infection	1A00-1C4Z	Approved	[32]
Dorzolamide	DMA17D0	Ocular hypertension	9C61.01	Approved	[33]
Chlorothiazide	DMLHESP	Chronic heart failure	BD1Z	Approved	[34]
Ethoxzolamide	DMVO4ED	Glaucoma/ocular hypertension	9C61	Approved	[35]
Dichlorphenamide	DMH7IDQ	Chronic glaucoma	9C61.0Z	Approved	[35]
Cyclothiazide	DMJ4AWC	Congestive heart failure	BD10	Approved	[36]
Ethinamate	DMK57GB	Insomnia	7A00-7A0Z	Approved	[37]
Benzthiazide	DMQWZ0H	High blood pressure	BA00	Approved	[38]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[22]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[23]

Drug(s) Targeting Carbonic anhydrase (CA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sulfamylon	DMIO1K0	Bacterial infection	1A00-1C4Z	Approved	[21]
Quinethazone	DMWCOSR	Hypertension	BA00-BA04	Approved	[39]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[22]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[23]
PHENOL	DM1QSM3	N. A.	N. A.	Phase 2/3	[22]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[24]
SULFAMIDE	DMMAS3K	N. A.	N. A.	Phase 1	[40]
FERULIC ACID	DMJC7NF	Discovery agent	N.A.	Patented	[23]
PMID30074415-Compound-21	DM3NPOU	N. A.	N. A.	Patented	[41]
Imatinib and nilotinib derivative 2	DM34NZ8	Cas mediated disorder	N.A.	Patented	[41]

Drug(s) Targeting Carbonic anhydrase IV (CA-IV)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sulfamylon	DMIO1K0	Bacterial infection	1A00-1C4Z	Approved	[42]
Brinzolamide	DMBAPFG	Ocular hypertension	9C61.01	Approved	[28]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[22]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[23]
PHENOL	DM1QSM3	N. A.	N. A.	Phase 2/3	[22]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[24]
Sodium pyruvate	DMST6A3	Asthma	CA23	Phase 1/2	[43]
SULFAMIDE	DMMAS3K	N. A.	N. A.	Phase 1	[40]
FERULIC ACID	DMJC7NF	Discovery agent	N.A.	Patented	[23]
SPERMINE	DMD4BFY	N. A.	N. A.	Terminated	[26]

Drug(s) Targeting Prostaglandin G/H synthase 1 (COX-1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Naproxen	DMZ5RGV	Bursitis		Approved	[44]
Mesalazine	DMOL5IU	Diverticulitis		Approved	[45]
Eicosapentaenoic acid/docosa-hexaenoic acid	DMMUCG4	Hypertriglyceridemia	5C80.1	Approved	[46]
Bromfenac	DMKB79O	Pain	MG30-MG3Z	Approved	[47]
Aminosalicylic Acid	DMENSL5	Crohn disease	DD70	Approved	[28]
Flufenamic Acid	DMC8VNH	Dysmenorrhea	GA34.3	Approved	[48]
Piroxicam	DMTK234	Osteoarthritis	FA00-FA05	Approved	[28]
Suprofen	DMKXJZ7	Miosis	LA11.62	Approved	[49]
Gamma-Homolinolenic acid	DMSXKYG	Malnutrition	5B50-5B71	Approved	[50]
FENBUFEN	DMXGDFK	Arthritis	FA20	Approved	[51]

Drug(s) Transported By Monocarboxylate transporter 1 (SLC16A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[52]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[13]
Gamma Hydroxybutyric Acid	DMGBKVD	Narcolepsy	7A20	Approved	[53]
Pyruvic acid	DM7Q41G	Malnutrition	5B50-5B71	Approved	[54]
Gabapentin enacarbil	DMJY2TM	Postherpetic neuralgia	1E91.5	Phase 2	[55]
Pyroglutamic Acid	DMROZUA	Discovery agent	N.A.	Investigative	[56]
Butanoic Acid	DMTAJP7	Discovery agent	N.A.	Investigative	[55]
Hydroxyacetic Acid	DMQFBH6	Discovery agent	N.A.	Investigative	[57]
biotin	DMKMCE1	Discovery agent	N.A.	Investigative	[58]
Milchsaure	DM462BT	Pruritus	EC90	Investigative	[59]

Drug(s) Transported By Monocarboxylate transporter 2 (SLC16A7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[60]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[60]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[60]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Propicillin	DMWDHUZ	Bacterial infection	1A00-1C4Z	Approved	[60]
Milchsaure	DM462BT	Pruritus	EC90	Investigative	[61]

Drug(s) Transported By Probable small intestine urate exporter (SLC17A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pravastatin	DM6A0X7	Adult acute monocytic leukemia		Approved	[11]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[11]
Phosphate	DMUXQG7	Constipation	DD91.1	Approved	[11]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[11]

Drug(s) Transported By Sodium-coupled monocarboxylate transporter 2 (SLC5A12)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Gamma Hydroxybutyric Acid	DMGBKVD	Narcolepsy	7A20	Approved	[10]
Benzoic Acid	DMKB9FI	Alopecia areata	ED70.2	Approved	[10]

Drug(s) Metabolized By Cytochrome P450 2C9 (CYP2C9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[62]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[63]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[64]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[65]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[66]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[65]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[67]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[68]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[69]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[70]

Drug(s) Affected By Solute carrier family 22 member 6 (SLC22A6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[71]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[19]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[72]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[19]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[19]
Succinic acid	DMDWICP	Malnutrition	5B50-5B71	Approved	[73]
Mefenamic acid	DMK7HFI	Dysmenorrhea	GA34.3	Approved	[19]
Probenecid	DMMFWOJ	Acute gonococcal cervicitis		Approved	[74]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[19]
Ketoprofen	DMRKXPT	Bursitis		Approved	[19]

Drug(s) Affected By Organic anion transporter 7 (SLC22A9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[19]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[75]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[76]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[77]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[19]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[19]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[79]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[80]
Mefenamic acid	DMK7HFI	Dysmenorrhea	GA34.3	Approved	[19]

Drug(s) Affected By Solute carrier family 22 member 11 (SLC22A11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[19]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[80]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[19]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[19]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[81]
Mefenamic acid	DMK7HFI	Dysmenorrhea	GA34.3	Approved	[19]
Probenecid	DMMFWOJ	Acute gonococcal cervicitis		Approved	[82]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[19]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[83]
Ketoprofen	DMRKXPT	Bursitis		Approved	[19]

Drug(s) Affected By Solute carrier family 22 member 7 (SLC22A7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[19]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[84]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[76]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[85]
Allopurinol	DMLPAOB	Gout	FA25	Approved	[85]
Bumetanide	DMRV7H0	Congestive heart failure	BD10	Approved	[85]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[85]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[85]
Tetracycline	DMZA017	Acne vulgaris	ED80	Approved	[85]
Ranitidine	DM0GUSX	Gastric ulcer	DA60	Approved	[86]

Drug(s) Affected By Aldo-keto reductase family 1 member C3 (AKR1C3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[87]
Meclofenamic acid	DM05FXR	Ankylosing spondylitis	FA92.0	Approved	[15]
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[88]
Levonorgestrel	DM1DP7T	Atypical endometrial hyperplasia		Approved	[89]
Desogestrel	DM27U4Y	Contraception	QA21	Approved	[89]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[15]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[90]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[91]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[92]
Glimepiride	DM5FSJA	Diabetic complication	5A2Y	Approved	[93]

Drug(s) Affected By Aldo-keto reductase family 1 member C1 (AKR1C1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[94]
Meclofenamic acid	DM05FXR	Ankylosing spondylitis	FA92.0	Approved	[15]
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[88]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[95]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[15]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[96]
Glimepiride	DM5FSJA	Diabetic complication	5A2Y	Approved	[93]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[95]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[15]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[97]

Drug(s) Affected By Aldo-keto reductase family 1 member C2 (AKR1C2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Meclofenamic acid	DM05FXR	Ankylosing spondylitis	FA92.0	Approved	[15]
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[88]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[98]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[15]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[75]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[99]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[15]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[97]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[100]
Glibenclamide	DM8JXPZ	Diabetic complication	5A2Y	Approved	[93]

Drug(s) Affected By Transcription factor MafF (MAFF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[101]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[102]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[103]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[75]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[104]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[105]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[106]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[107]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[108]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[109]

Drug(s) Affected By Proteasome subunit beta type-9 (PSMB9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[110]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[111]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[112]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[113]
Sodium lauryl sulfate	DMLJ634	Constipation	DD91.1	Approved	[18]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[114]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[115]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[20]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[116]

Drug(s) Affected By Proteasome subunit beta type-10 (PSMB10)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[117]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[118]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[119]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[119]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[120]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[79]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[121]
Sodium lauryl sulfate	DMLJ634	Constipation	DD91.1	Approved	[18]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[122]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[20]

Drug(s) Affected By Interleukin-8 (CXCL8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrocortisone	DMGEMB7	Acne vulgaris	ED80	Approved	[123]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[124]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[125]
Pantothenic acid	DM091H2	Vitamin deficiency	5B55-5B71	Approved	[126]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[127]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[128]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[129]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[130]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[131]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[129]

Drug(s) Affected By Cytochrome P450 4A11 (CYP4A11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Clofibrate	DMPC1J7	Dysbetalipoproteinemia	5C80.2	Approved	[132]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[17]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[133]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[104]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[134]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[134]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[17]
Etodolac	DM6WJO9	Osteoarthritis	FA00-FA05	Approved	[17]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[17]
Oxaprozin	DM9UB0P	Osteoarthritis	FA00-FA05	Approved	[17]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Carbonic anhydrase (CA)	TTUNARX	NOUNIPROTAC	Inhibitor	[7]
Carbonic anhydrase I (CA-I)	TTHQPL7	CAH1_HUMAN	Inhibitor	[8]
Carbonic anhydrase II (CA-II)	TTANPDJ	CAH2_HUMAN	Inhibitor	[8]
Carbonic anhydrase IV (CA-IV)	TTZHA0O	CAH4_HUMAN	Inhibitor	[8]
Carbonic anhydrase VI (CA-VI)	TTCFSPE	CAH6_HUMAN	Inhibitor	[8]
Carbonic anhydrase XII (CA-XII)	TTSYM0R	CAH12_HUMAN	Inhibitor	[8]
Prostaglandin G/H synthase 1 (COX-1)	TT8NGED	PGH1_HUMAN	Inhibitor	[9]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Sodium-coupled monocarboxylate transporter 2 (SLC5A12)	DTM301H	SC5AC_HUMAN	Substrate	[10]
Probable small intestine urate exporter (SLC17A4)	DTHE530	S17A4_HUMAN	Substrate	[11]
Monocarboxylate transporter 2 (SLC16A7)	DTLT3UG	MOT2_HUMAN	Substrate	[12]
Monocarboxylate transporter 1 (SLC16A1)	DT342ZG	MOT1_HUMAN	Substrate	[13]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2C9 (CYP2C9) Main DME	DE5IED8	CP2C9_HUMAN	Substrate	[14]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Aldo-keto reductase family 1 member C1 (AKR1C1)	OTQKR4CM	AK1C1_HUMAN	Gene/Protein Processing	[15]
Aldo-keto reductase family 1 member C2 (AKR1C2)	OTQ2XMO3	AK1C2_HUMAN	Gene/Protein Processing	[16]
Aldo-keto reductase family 1 member C3 (AKR1C3)	OTU2SXBA	AK1C3_HUMAN	Gene/Protein Processing	[15]
Cytochrome P450 4A11 (CYP4A11)	OTPU5J0S	CP4AB_HUMAN	Gene/Protein Processing	[17]
Interleukin-8 (CXCL8)	OTS7T5VH	IL8_HUMAN	Gene/Protein Processing	[18]
Organic anion transporter 7 (SLC22A9)	OTO4BJCC	S22A9_HUMAN	Gene/Protein Processing	[19]
Proteasome subunit beta type-10 (PSMB10)	OTURUR9B	PSB10_HUMAN	Gene/Protein Processing	[20]
Proteasome subunit beta type-9 (PSMB9)	OTFV57T8	PSB9_HUMAN	Gene/Protein Processing	[20]
Solute carrier family 22 member 11 (SLC22A11)	OTAJLNJZ	S22AB_HUMAN	Gene/Protein Processing	[19]
Solute carrier family 22 member 6 (SLC22A6)	OTKRCBVM	S22A6_HUMAN	Gene/Protein Processing	[19]

References

• [1] The influence of various factors on the human resident skin flora. Semin Dermatol. 1990 Dec;9(4):305-8.
• [2] A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
• [3] Fully biodegradable coronary stents : progress to date. Am J Cardiovasc Drugs. 2008;8(5):305-14.
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4306).
• [5] Covalent modification of cyclooxygenase-2 (COX-2) by 2-acetoxyphenyl alkyl sulfides, a new class of selective COX-2 inactivators. J Med Chem. 1998 Nov 19;41(24):4800-18.
• [6] Protein binding of tolmetin. Clin Pharmacol Ther. 1978 Dec;24(6):694-705.
• [7] Carbonic anhydrase inhibitors: Inhibition of the new membrane-associated isoform XV with phenols. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3593-6.
• [8] Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8.
• [9] The C50T polymorphism of the cyclooxygenase-1 gene and the risk of thrombotic events during low-dose therapy with acetyl salicylic acid. Thromb Haemost. 2008 Jul;100(1):70-5.
• [10] Sodium-coupled monocarboxylate transporters in normal tissues and in cancer. AAPS J. 2008;10(1):193-9.
• [11] A Na+-phosphate cotransporter homologue (SLC17A4 protein) is an intestinal organic anion exporter. Am J Physiol Cell Physiol. 2012 Jun 1;302(11):C1652-60.
• [12] Clinical and Functional Relevance of the Monocarboxylate Transporter Family in Disease Pathophysiology and Drug Therapy. Clin Transl Sci. 2018 Jul;11(4):352-364.
• [13] H+-coupled nutrient, micronutrient and drug transporters in the mammalian small intestine. Exp Physiol. 2007 Jul;92(4):603-19.
• [14] Aromatic hydroxylation of salicylic acid and aspirin by human cytochromes P450. Eur J Pharm Sci. 2015 Jun 20;73:49-56.
• [15] Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs. Chem Biol Interact. 2009 Mar 16;178(1-3):221-7.
• [16] A new in vitro method for identifying chemical sensitizers combining peptide binding with ARE/EpRE-mediated gene expression in human skin cells. Cutan Ocul Toxicol. 2010 Sep;29(3):171-92.
• [17] Effects of acidic non-steroidal anti-inflammatory drugs on human cytochrome P450 4A11 activity: Roles of carboxylic acid and a sulfur atom in potent inhibition by sulindac sulfide. Chem Biol Interact. 2023 Sep 1;382:110644. doi: 10.1016/j.cbi.2023.110644. Epub 2023 Jul 25.
• [18] CXCL14 downregulation in human keratinocytes is a potential biomarker for a novel in vitro skin sensitization test. Toxicol Appl Pharmacol. 2020 Jan 1;386:114828. doi: 10.1016/j.taap.2019.114828. Epub 2019 Nov 14.
• [19] Interactions of human organic anion transporters and human organic cation transporters with nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther. 2002 Nov;303(2):534-9.
• [20] Pathophysiological roles of aldo-keto reductases (AKR1C1 and AKR1C3) in development of cisplatin resistance in human colon cancers. Chem Biol Interact. 2013 Feb 25;202(1-3):234-42.
• [21] Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
• [22] Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
• [23] Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
• [24] Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-r... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4282-6.
• [25] An Antibody-Drug Conjugate Targeting MUC1-Associated Carbohydrate CA6 Shows Promising Antitumor Activities. Mol Cancer Ther. 2020 Aug;19(8):1660-1669.
• [26] Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22.
• [27] Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
• [28] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [29] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2597).
• [30] Understanding the Dual Inhibition of COX-2 and Carbonic Anhydrase-II by Celecoxib and CG100649 Using Density Functional Theory Calculations and other Molecular Modelling Approaches. Protein Pept Lett. 2015;22(10):903-12.
• [31] Carbonic anhydrase inhibitors. Inhibition of the newly isolated murine isozyme XIII with anions. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5435-9.
• [32] Sulfonamide linked neoglycoconjugates--a new class of inhibitors for cancer-associated carbonic anhydrases. J Med Chem. 2010 Apr 8;53(7):2913-26.
• [33] Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides. Bioorg Med Chem. 2009 Jul 15;17(14):5054-8.
• [34] Localization of diuretic effects along the loop of Henle: an in vivo microperfusion study in rats. Clin Sci (Lond). 2000 Apr;98(4):481-8.
• [35] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [36] Selective effect of thiazides on the human osteoblast-like cell line MG-63. Kidney Int. 1996 Nov;50(5):1476-82.
• [37] Inhibition of carbonic anhydrases I and II by N-unsubstituted carbamate esters. J Biol Chem. 1992 Dec 15;267(35):25044-50.
• [38] Nature of the inhibition of carbonic anhydrase by acetazolamide and benzthiazide. J Pharmacol Exp Ther. 1961 Mar;131:271-4.
• [39] Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for th... Bioorg Med Chem Lett. 2008 Apr 15;18(8):2567-73.
• [40] Carbonic anhydrase inhibitors: crystallographic and solution binding studies for the interaction of a boron-containing aromatic sulfamide with mamm... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3601-5.
• [41] Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008-2018).Expert Opin Ther Pat. 2018 Oct;28(10):729-740.
• [42] Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides. Bioorg Med Chem Lett. 2005 Feb 15;15(4):1149-54.
• [43] Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with carboxylates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):573-8.
• [44] Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20.
• [45] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [46] Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9.
• [47] Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006 Jun;22(6):1133-40.
• [48] Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
• [49] Differential binding mode of diverse cyclooxygenase inhibitors. J Mol Graph Model. 2002 Mar;20(5):359-71.
• [50] Differential metabolism of dihomo-gamma-linolenic acid and arachidonic acid by cyclo-oxygenase-1 and cyclo-oxygenase-2: implications for cellular synthesis of prostaglandin E1 and prostaglandin E2. Biochem J. 2002 Jul 15;365(Pt 2):489-96.
• [51] Fenbufen based 3-[5-(substituted aryl)-1,3,4-oxadiazol-2-yl]-1-(biphenyl-4-yl)propan-1-ones as safer antiinflammatory and analgesic agents. Eur J Med Chem. 2009 Sep;44(9):3798-804.
• [52] Circadian rhythms in gene expression: Relationship to physiology, disease, drug disposition and drug action. Adv Drug Deliv Rev. 2010 Jul 31;62(9-10):904-17.
• [53] Flavonoids modulate monocarboxylate transporter-1-mediated transport of gamma-hydroxybutyrate in vitro and in vivo. Drug Metab Dispos. 2007 Feb;35(2):201-8.
• [54] AR-C155858 is a potent inhibitor of monocarboxylate transporters MCT1 and MCT2 that binds to an intracellular site involving transmembrane helices 7-10. Biochem J. 2010 Jan 15;425(3):523-30.
• [55] Overview of the proton-coupled MCT (SLC16A) family of transporters: characterization, function and role in the transport of the drug of abuse gamma-hydroxybutyric acid. AAPS J. 2008 Jun;10(2):311-21.
• [56] Interaction of atorvastatin with the human glial transporter SLC16A1. Eur J Pharmacol. 2016 Oct 5;788:248-254.
• [57] Cidofovir peptide conjugates as prodrugs. Journal of Organometallic Chemistry, 2005, 690(10):2673-2678.
• [58] Biotin. Biofactors. 2009 Jan-Feb;35(1):36-46.
• [59] Distribution of monocarboxylate transporters MCT1-MCT8 in rat tissues and human skeletal muscle. Appl Physiol Nutr Metab. 2006 Feb;31(1):31-9.
• [60] Monocarboxylate Transporters in Drug Disposition: Role in the Toxicokinetics and Toxicodynamics of the Drug of Abuse GHB.
• [61] Characterization of the high-affinity monocarboxylate transporter MCT2 in Xenopus laevis oocytes. Biochem J. 1999 Aug 1;341 ( Pt 3):529-35.
• [62] Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
• [63] Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
• [64] Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
• [65] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [66] Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
• [67] Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
• [68] New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
• [69] A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
• [70] A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
• [71] P-gp, MRP2 and OAT1/OAT3 mediate the drug-drug interaction between resveratrol and methotrexate. Toxicol Appl Pharmacol. 2016 Sep 1;306:27-35. doi: 10.1016/j.taap.2016.06.030. Epub 2016 Jul 1.
• [72] Potent Inhibitors of Organic Anion Transporters 1 and 3 From Natural Compounds and Their Protective Effect on Aristolochic Acid Nephropathy. Toxicol Sci. 2020 Jun 1;175(2):279-291. doi: 10.1093/toxsci/kfaa033.
• [73] Lack of efflux of diglycolic acid from proximal tubule cells leads to its accumulation and to toxicity of diethylene glycol. Toxicol Lett. 2023 Apr 15;379:48-55. doi: 10.1016/j.toxlet.2023.03.007. Epub 2023 Mar 22.
• [74] Inhibition of organic anion transporter (OAT) activity by cigarette smoke condensate. Toxicol In Vitro. 2017 Oct;44:27-35.
• [75] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [76] Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23. doi: 10.1007/s00204-013-1169-3. Epub 2013 Nov 30.
• [77] Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes. Front Pharmacol. 2016 Apr 26;7:111.
• [78] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [79] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [80] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [81] Vitamin D3 transactivates the zinc and manganese transporter SLC30A10 via the Vitamin D receptor. J Steroid Biochem Mol Biol. 2016 Oct;163:77-87.
• [82] Neonicotinoid pesticides poorly interact with human drug transporters. J Biochem Mol Toxicol. 2019 Oct;33(10):e22379. doi: 10.1002/jbt.22379. Epub 2019 Jul 31.
• [83] Multiple drug transporters mediate the placental transport of sulpiride. Arch Toxicol. 2017 Dec;91(12):3873-3884. doi: 10.1007/s00204-017-2008-8. Epub 2017 Jun 9.
• [84] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [85] Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol. 2005 May;57(5):573-8.
• [86] A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45.
• [87] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [88] Substrate specificity of human 3(20)alpha-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines. Biol Pharm Bull. 2002 Apr;25(4):441-5.
• [89] Progestins as inhibitors of the human 20-ketosteroid reductases, AKR1C1 and AKR1C3. Chem Biol Interact. 2011 May 30;191(1-3):227-33.
• [90] In-vivo effects of simvastatin and rosuvastatin on global gene expression in peripheral blood leucocytes in a human inflammation model. Pharmacogenet Genomics. 2008 Feb;18(2):109-20.
• [91] AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids. Chem Biol Interact. 2009 Mar 16;178(1-3):138-44.
• [92] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [93] Initro inhibition of AKR1Cs by sulphonylureas and the structural basis. Chem Biol Interact. 2015 Oct 5;240:310-5.
• [94] Progestin effects on expression of AKR1C1-AKR1C3, SRD5A1 and PGR in the Z-12 endometriotic epithelial cell line. Chem Biol Interact. 2013 Feb 25;202(1-3):218-25.
• [95] Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase. Cancer Res. 1999 Feb 1;59(3):607-14.
• [96] Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007 Jun;98(6):890-9.
• [97] Thyroid hormone responsive genes in cultured human fibroblasts. J Clin Endocrinol Metab. 2005 Feb;90(2):936-43.
• [98] Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
• [99] Aberrantly expressed genes in HaCaT keratinocytes chronically exposed to arsenic trioxide. Biomark Insights. 2011 Feb 8;6:7-16.
• [100] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [101] Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1. Redox Biol. 2020 Jan;28:101321. doi: 10.1016/j.redox.2019.101321. Epub 2019 Sep 5.
• [102] Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
• [103] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [104] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [105] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [106] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [107] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [108] Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Arch Toxicol. 2020 Apr;94(4):1151-1172. doi: 10.1007/s00204-020-02691-9. Epub 2020 Mar 10.
• [109] Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
• [110] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [111] Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
• [112] Effects of lithium and valproic acid on gene expression and phenotypic markers in an NT2 neurosphere model of neural development. PLoS One. 2013;8(3):e58822.
• [113] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [114] Inhibition of PARP1 Increases IRF-dependent Gene Transcription in Jurkat Cells. Curr Med Sci. 2019 Jun;39(3):356-362. doi: 10.1007/s11596-019-2043-1. Epub 2019 Jun 17.
• [115] A transcriptomics-based in vitro assay for predicting chemical genotoxicity in vivo. Carcinogenesis. 2012 Jul;33(7):1421-9.
• [116] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
• [117] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [118] Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers. Clin Breast Cancer. 2013 Oct;13(5):401-8.
• [119] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [120] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [121] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [122] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [123] Monomeric and oligomeric flavanols maintain the endogenous glucocorticoid response in human macrophages in pro-oxidant conditions in vitro. Chem Biol Interact. 2018 Aug 1;291:237-244.
• [124] Nicotine up-regulates IL-8 expression in human gingival epithelial cells following stimulation with IL-1 or P. gingivalis lipopolysaccharide via nicotinic acetylcholine receptor signalling. Arch Oral Biol. 2012 May;57(5):483-90. doi: 10.1016/j.archoralbio.2011.10.007. Epub 2011 Nov 25.
• [125] Ca(2+) Signaling and IL-8 Secretion in Human Testicular Peritubular Cells Involve the Cation Channel TRPV2. Int J Mol Sci. 2018 Sep 19;19(9):2829. doi: 10.3390/ijms19092829.
• [126] Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78. doi: 10.1111/j.1600-0625.2009.00884.x. Epub 2009 Apr 8.
• [127] Nitrogen mustard prevents transport of Fra-1 into the nucleus to promote c-Fos- and FosB-dependent IL-8 induction in injured mouse epidermis. Toxicol Lett. 2020 Feb 1;319:256-263. doi: 10.1016/j.toxlet.2019.10.006. Epub 2019 Oct 19.
• [128] ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
• [129] An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
• [130] Gypenosides protect retinal pigment epithelium cells from oxidative stress. Food Chem Toxicol. 2018 Feb;112:76-85.
• [131] Nitric oxide synthase inhibitors attenuate ozone-induced airway inflammation in guinea pigs. Possible role of interleukin-8. Am J Respir Crit Care Med. 2000 Jan;161(1):249-56. doi: 10.1164/ajrccm.161.1.9804096.
• [132] Regulation of CYP4A expression by bezafibrate in primary culture of rat and human hepatocytes: interspecies difference and influence of N-acetylcysteine. Toxicol In Vitro. 2009 Oct;23(7):1259-67.
• [133] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [134] Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.